Romiplostim biosimilar (Enzene Biosciences)

罗米司亭生物类似药 (Enzene Biosciences)

Report date: 2022/01/14 13:23:58

Base Information

Drug NameRomiplostim biosimilar (Enzene Biosciences)
Drug Alias Name267639-76-9
ClassificationBiologics > Biosimilar
Mechanisms of ActionThrombopoietin receptor agonists
TargetsThrombopoietin receptor
Therapy Area/IndicationsPurpura, Thrombocytopenic, Idiopathic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesEnzene Biosciences Ltd
China Registration ClassN/A

Develop Information

Active CompaniesEnzene Biosciences Ltd
Inactive CompaniesN/A
Active IndicationsPurpura, Thrombocytopenic, Idiopathic
Inactive IndicationsN/A

Other Information

ATC CodeB02BX04
Related LinksN/A